Recent advances in early-onset severe retinal degeneration: more than just basic research

Markus N Preising; Steffen Heegaard

doi:10.1016/j.molmed.2003.12.002

Recent advances in early-onset severe retinal degeneration: more than just basic research

12 Citationer (Scopus)

Abstract

Successful treatment of early-onset sever retinal degeneration (EOSRD) in an animal model of the disease has provided the first proof-o-principle for retinal gene therapy of higher mammals. Currently, large sets of DNA samples are screened to identify patients with Leber's congenital amaurosis (LCA) carrying mutations in RPE65 as possible candidates for gene therapy trials. Research into EOSRD and LCA aims to identify the function of proteins involved or phenotypic changes upon mutation. These data will be used to describe the disease phenotype and identify parameters that can predict the outcome of gene therapy trials.

Originalsprog	Engelsk
Tidsskrift	Trends in Molecular Medicine
Vol/bind	10
Udgave nummer	2
Sider (fra-til)	51-4
Antal sider	4
ISSN	1471-4914
DOI	https://doi.org/10.1016/j.molmed.2003.12.002
Status	Udgivet - feb. 2004
Udgivet eksternt	Ja

Adgang til dokumentet

10.1016/j.molmed.2003.12.002

Citationsformater

@article{98e3886f2e6048d89bb32b871c6950d8,

title = "Recent advances in early-onset severe retinal degeneration: more than just basic research",

abstract = "Successful treatment of early-onset sever retinal degeneration (EOSRD) in an animal model of the disease has provided the first proof-o-principle for retinal gene therapy of higher mammals. Currently, large sets of DNA samples are screened to identify patients with Leber's congenital amaurosis (LCA) carrying mutations in RPE65 as possible candidates for gene therapy trials. Research into EOSRD and LCA aims to identify the function of proteins involved or phenotypic changes upon mutation. These data will be used to describe the disease phenotype and identify parameters that can predict the outcome of gene therapy trials.",

keywords = "Acyltransferases/genetics, Adaptor Proteins, Signal Transducing, Animals, Carrier Proteins/genetics, Cytoskeletal Proteins, Disease Models, Animal, Eye Proteins, Genetic Predisposition to Disease/genetics, Genetic Therapy, Guanylate Cyclase/genetics, Homeodomain Proteins/genetics, Humans, Mice, Mice, Knockout, Mutation/genetics, Optic Atrophy, Hereditary, Leber/genetics, Photoreceptor Cells, Vertebrate/metabolism, Pigment Epithelium of Eye/metabolism, Proteins/genetics, Receptors, Cell Surface/genetics, Retinal Degeneration/genetics, Trans-Activators/genetics, cis-trans-Isomerases",

author = "Preising, {Markus N} and Steffen Heegaard",

year = "2004",

month = feb,

doi = "10.1016/j.molmed.2003.12.002",

language = "English",

volume = "10",

pages = "51--4",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Recent advances in early-onset severe retinal degeneration

T2 - more than just basic research

AU - Preising, Markus N

AU - Heegaard, Steffen

PY - 2004/2

Y1 - 2004/2

N2 - Successful treatment of early-onset sever retinal degeneration (EOSRD) in an animal model of the disease has provided the first proof-o-principle for retinal gene therapy of higher mammals. Currently, large sets of DNA samples are screened to identify patients with Leber's congenital amaurosis (LCA) carrying mutations in RPE65 as possible candidates for gene therapy trials. Research into EOSRD and LCA aims to identify the function of proteins involved or phenotypic changes upon mutation. These data will be used to describe the disease phenotype and identify parameters that can predict the outcome of gene therapy trials.

AB - Successful treatment of early-onset sever retinal degeneration (EOSRD) in an animal model of the disease has provided the first proof-o-principle for retinal gene therapy of higher mammals. Currently, large sets of DNA samples are screened to identify patients with Leber's congenital amaurosis (LCA) carrying mutations in RPE65 as possible candidates for gene therapy trials. Research into EOSRD and LCA aims to identify the function of proteins involved or phenotypic changes upon mutation. These data will be used to describe the disease phenotype and identify parameters that can predict the outcome of gene therapy trials.

KW - Acyltransferases/genetics

KW - Adaptor Proteins, Signal Transducing

KW - Animals

KW - Carrier Proteins/genetics

KW - Cytoskeletal Proteins

KW - Disease Models, Animal

KW - Eye Proteins

KW - Genetic Predisposition to Disease/genetics

KW - Genetic Therapy

KW - Guanylate Cyclase/genetics

KW - Homeodomain Proteins/genetics

KW - Humans

KW - Mice

KW - Mice, Knockout

KW - Mutation/genetics

KW - Optic Atrophy, Hereditary, Leber/genetics

KW - Photoreceptor Cells, Vertebrate/metabolism

KW - Pigment Epithelium of Eye/metabolism

KW - Proteins/genetics

KW - Receptors, Cell Surface/genetics

KW - Retinal Degeneration/genetics

KW - Trans-Activators/genetics

KW - cis-trans-Isomerases

U2 - 10.1016/j.molmed.2003.12.002

DO - 10.1016/j.molmed.2003.12.002

M3 - Review

C2 - 15106616

SN - 1471-4914

VL - 10

SP - 51

EP - 54

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 2

ER -

Recent advances in early-onset severe retinal degeneration: more than just basic research

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater